Will Contrave's Cardiovascular Risks Wear Thin on FDA's Decision?

June 10, 2014 5:07 PM

16 0

The U.S. Food and Drug Administration (FDA) may finally approve the hot new diet pill Contrave, currently renamed NB32. The health organization is expected to make a decision Wednesday, according to analysts.

In 2011, Orexigen Therapeutics' received the thumbs-down from the FDA regarding certain safety issues pertaining to cardiovascular health. In order to resubmit an application for FDA review and approval, Orexigen conducted a multi-year study to examine research that Contrave could be safe for patie...

Also read: FDA OKs 2nd gene therapy for blood cancer; 1st for adults

Read more

To category page